IDXG - Interpace Diagnostics Group, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.7510
-0.0190 (-2.47%)
At close: 4:00PM EDT

0.7510 0.00 (0.00%)
After hours: 5:11PM EDT

Stock chart is not supported by your current browser
Previous Close 0.7700
Open 0.7501
Bid 0.7510 x 3000
Ask 0.7900 x 800
Day's Range 0.7320 - 0.7750
52 Week Range 0.6700 - 1.7800
Volume 127,312
Avg. Volume 240,660
Market Cap 29.231M
Beta (3Y Monthly) 1.92
PE Ratio (TTM) N/A
EPS (TTM) -0.4850
Earnings Date Aug 14, 2017 - Aug 18, 2017
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 3.22
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents

    Edited Transcript of IDXG earnings conference call or presentation 13-Aug-19 12:30pm GMT

    Q2 2019 Interpace Diagnostics Group Inc Earnings Call

  • GlobeNewswire

    Predictive Oncology Inc. Reports Second Quarter 2019 Financial Results and Provides Corporate Update

    MINNEAPOLIS, Aug. 19, 2019 -- Predictive Oncology Inc., (NASDAQ: POAI) (“Predictive Oncology ” or “the Company”) an artificial intelligence (AI) and data-driven functional.

  • GlobeNewswire

    Interpace Diagnostics Reports Second Quarter 2019 Financial Results and Provides Business Update

    Second Quarter Revenue Grew 14% Over the Prior Year and 19% Year to Date Over the Prior Year Acquired Growing BioPharma Services Business Net Revenue Guidance Increased.

  • ACCESSWIRE

    Interpace Diagnostics Group, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 13, 2019 / Interpace Diagnostics Group, Inc. (NASDAQ: IDXG ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August 13, ...

  • GlobeNewswire

    Interpace Diagnostics to Host Conference Call and Webcast to Discuss Second Quarter 2019 Financial Results on Tuesday, August 13, 2019

    PARSIPPANY, NJ, Aug. 06, 2019 -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it will report its second quarter 2019 financial results on Tuesday,.

  • GlobeNewswire

    Interpace Diagnostics Announces Contract with Blue Cross Blue Shield of Michigan

    Interpace Diagnostics Group, Inc. (IDXG) announced today that it has contracted with Blue Cross Blue Shield (BCBS) of Michigan, a not-for-profit independent member of the Blue Cross Blue Shield Association with 4.5 million members in the State of Michigan, making it the largest payer in the State, along with another 1.6 million members across multiple other States. The contract makes the ThyGeNEXT® and ThyraMIR® tests both covered services as well as in-network services for their total of 6 million members.

  • GlobeNewswire

    Interpace Announces Contract with Blue Shield of California for ThyGeNEXT® & ThyraMIR®

    Interpace Diagnostics Group, Inc. (IDXG) announced today that it has entered in to a contract with Blue Shield of California, a not-for-profit independent member of the Blue Cross Blue Shield Association making ThyGeNEXT and ThyraMIR tests in-network services for their 4 million lives.  Blue Shield originally granted coverage for ThyGeNEXT and ThyraMIR in March of 2018 and now members will be able to access Interpace’s molecular thyroid tests on an in-network basis, which will limit their out of pocket expenses and optimize their benefits in accordance with their in-network benefit levels. According to the American Cancer Society, thyroid cancer is the most rapidly increasing cancer in the U.S., tripling in the past three decades.

  • GlobeNewswire

    Interpace Announces New Agreement with SelectHealth

    Interpace Diagnostics Group, Inc. (IDXG) announced today that it has reached an agreement with SelectHealth (a plan associated with Intermountain Healthcare) to provide its proprietary thyroid cancer assays, ThyGeNEXT® and ThyraMIR® to SelectHealth’s more than 850,000 members in Utah and Idaho. Physicians across SelectHealth’s entire network will now be able to utilize Interpace’s thyroid tests to assess indeterminate thyroid nodules thereby providing physicians with additional diagnostic options.

  • Benzinga

    Interpace Diagnostics Partners With AI Specialist To Diagnose Thyroid Cancer

    Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced it completed an agreement with the Helomics division of Predictive Oncology (NASDAQ: POAI), which is focused on applying artificial intelligence to personalized medicine and drug discovery. It's estimated that the treatment market for thyroid cancer was valued at approximately $340 million in 2018 and is expected to reach $2.1 billion by the end of 2025. Under the agreement, the companies will develop products to diagnose and assess the risk for thyroid cancer as well as provide appropriate therapeutic recommendations.

  • GlobeNewswire

    Interpace Diagnostics Enters Agreement with Predictive Oncology to Enhance Diagnosis of Thyroid Cancer Via AI-Driven Analysis

    Interpace Diagnostics Group, Inc. (IDXG) (“Interpace” or the “Company), announced today that it has executed an agreement with the Helomics division of Predictive Oncology (NASDAQ:POAI), a company focused on applying artificial intelligence to personalized medicine and drug discovery. As part of this agreement, the Companies expect to develop a pipeline of products that work seamlessly together to diagnose and assess the risk for thyroid cancer as well as provide appropriate therapeutic recommendations by leveraging Interpace’s Thyroid products, ThyGeNEXT® and ThyraMIR®, coupled with Helomics’ patient-derived tumor profiling and AI platform known as “D-CHIP.” Under the plan for this phase of the agreement Helomics will build a model using Interpace’s existing clinical data which can be utilized to identify druggable targets for treatment of indolent and aggressive thyroid cancers.

  • Benzinga

    Cancer Genetics Sharply Higher After Interpace Buys Biopharma Unit

    Cancer Genetics (NASDAQ: CGIX ) shares are trading sharply higher after Interpace Diagnostics (NASDAQ: IDXG ) said it purchased the Biopharma Services unit of the Cancer Genetics. Interpace Diagnostics ...

  • GlobeNewswire

    Interpace Diagnostics Acquires Cancer Genetics’ Biopharma Services Business Supported by Investment from Ampersand Capital Partners

    Interpace Diagnostics Group, Inc. (IDXG) (“Interpace” or the “Company”), announced today that it has acquired assets and certain liabilities constituting the Biopharma Services business of Cancer Genetics, Inc. (CGIX) (the “BioPharma Business”) for approximately $23.5 million subject to certain adjustments. The acquisition is expected to create a leading oncology testing and service company in the clinical diagnostic and Biopharma markets, leveraging sophisticated assays, novel algorithms and custom service capabilities across the continuum of oncology from precancerous assessment to drug discovery and clinical trial support. In conjunction with this acquisition Ampersand Capital Partners, one of the leading private equity firms in the diagnostic/biopharma sector, agreed to invest $27M in Interpace in two tranches of newly issued convertible preferred stock, a portion of which will be subject to approval by Interpace’s shareholders.

  • Those Who Purchased Interpace Diagnostics Group (NASDAQ:IDXG) Shares Five Years Ago Have A 98% Loss To Show For It
    Simply Wall St.

    Those Who Purchased Interpace Diagnostics Group (NASDAQ:IDXG) Shares Five Years Ago Have A 98% Loss To Show For It

    Long term investing works well, but it doesn't always work for each individual stock. We really hate to see fellow...

  • GlobeNewswire

    Interpace Diagnostics Announces Coverage of Molecular Thyroid Testing by Independence Blue Cross

    Interpace Diagnostics Group, Inc. (IDXG) announced today that its ThyGeNEXT™ and ThyraMIR® tests for thyroid cancer are now covered by Independence Blue Cross (Independence), providing plan benefits coverage for its members who meet established medical criteria for the tests. Interpace’s testing is made available to its members by its strategic partner, LabCorp (LH), Independence’s primary lab services provider, through LabCorp’s Dianon Pathology specialty laboratory.

  • GlobeNewswire

    Interpace Diagnostics Announces Presentation at the World Congress on Thyroid Cancer

    Interpace Diagnostics Group, Inc. (IDXG), a fully integrated bioinformatics and commercial molecular diagnostic company, today announced that Dr. Sydney D. Finkelstein, Interpace’s Chief Scientific Officer, will present at the World Congress on Thyroid Cancer, which is being held in Rome, Italy from June 20-22, 2019. The presentation will detail outcomes of a study with patients using Interpace’s ThyGenX® and ThyGeNEXT® in combination with microRNA (miRNA) testing in indeterminate thyroid nodules. “I am excited to present findings from Interpace’s thyroid study at the World Congress on Thyroid Cancer,” stated Dr. Sydney D. Finkelstein, Interpace’s Chief Scientific Officer.

  • Thomson Reuters StreetEvents

    Edited Transcript of IDXG earnings conference call or presentation 13-May-19 8:30pm GMT

    Q1 2019 Interpace Diagnostics Group Inc Earnings Call

  • GlobeNewswire

    Interpace Diagnostics Reports First Quarter 2019 Financial Results and Provides Business Update

    Quarterly Revenue Grew to $6.0 Million, a 25% Increase Year-over-Year Annual 2019 Revenue Guidance of $27 to $28 Million, a 25% Increase Conference Call and Webcast.

  • GlobeNewswire

    Interpace Diagnostics BarreGEN® Data to be Presented at Digestive Disease Week

    PARSIPPANY, NJ, May 09, 2019 (GLOBE NEWSWIRE) --  Interpace Diagnostics Group, Inc. (IDXG) announced today that data from an independent study, which showed that BarreGEN® performed effectively as a biomarker tool for predicting risk of developing more advanced stages of disease prior to visible appearance of advanced histology, will be presented at the annual Digestive Disease Week® (“DDW”). The meeting will be held in San Diego, CA on May 18-21, 2019, and is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

  • GlobeNewswire

    Interpace Diagnostics to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results on Monday, May 13, 2019

    Interpace Diagnostics Group, Inc., (IDXG:NASDAQ) announced today that it will report its first quarter 2019 financial results after the close of market on Monday, May 13, 2019 at 4:30 p.m. ET. Interpace will host a conference call and webcast to discuss the Company’s financial results and provide a general business update. A webcast replay will be available on the company’s website (www.interpacediagnostics.com) approximately two hours following completion of the call and will be archived on the company’s website for 90 days.

  • GlobeNewswire

    Interpace Diagnostics Announces Publication of Important New Data on Thyroid Test Performance

    Interpace Diagnostics Group, Inc. (IDXG) (“Interpace” or “the Company”) announced today that data from its thyroid registry has been published in the peer reviewed publication Diagnostic Cytopathology in a paper called “Clinical impact of testing for mutation and microRNA’s in thyroid nodules.” The new data from over 300 samples was compiled from a two-year, real-world, retrospective study and highlighted the clinical utility of Interpace’s ThyGenX® thyroid oncogene panel in combination with ThyraMIR®, its micro-RNA classifier. Importantly, the study also showed that surgical decisions made with our combination thyroid tests were appropriately aligned with risk of malignancy over multiple years of clinical follow-up, which is consistent with a combination test that effectively rules-in and rules-out higher risk of malignancy.

  • Interpace Diagnostics Group, Inc.'s (NASDAQ:IDXG) Shift From Loss To Profit
    Simply Wall St.

    Interpace Diagnostics Group, Inc.'s (NASDAQ:IDXG) Shift From Loss To Profit

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Interpace Diagnostics Group, Inc.'s (NASDAQ:IDXG): Interpace Diagnostics Group, Inc. develops a...

  • GlobeNewswire

    Interpace Diagnostics Labs Receive College of American Pathology (CAP) Accreditation

    Interpace Diagnostics Group, Inc. (IDXG) announced today that it has received the College of American Pathologists (“CAP”) accreditation for its Pittsburgh, Pennsylvania and New Haven, Connecticut laboratories. Only after the Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) designation has been received can a laboratory apply for the more rigorous CAP accreditation.

  • GlobeNewswire

    Interpace Diagnostics Announces New York State Approval

    Interpace Diagnostics Group, Inc. (IDXG) announced today that it has received approval to launch ThyraMIR® diagnostic testing on formalin-fixed, paraffin-embedded (“FFPE”) tissue samples from thyroid nodules from the State of New York. ThyraMIR® is now the only molecular test approved to be used on indeterminate thyroid nodule samples presented via fine needle aspirates in RNA Retain®, cytology slides, and FFPE fixation in the State of New York. In combination with the previous New York State approval of the Company’s next-generation thyroid product, ThyGeNEXTÒ, physicians and patients now have increased access to Interpace’s thyroid product suite across a wide spectrum of specimen types providing a single point of access for molecular testing.

  • GlobeNewswire

    Interpace Diagnostics Announces New Coverage of Thyroid Testing by Medica

    Interpace Diagnostics Group, Inc. (IDXG) announced today that Medica, one of the largest health plans spanning numerous states throughout the Midwest, has extended coverage of both ThyGeNEXT™ and ThyraMIR® to its 1.3 million covered lives. Physicians across Medica’s entire network will now be able to utilize Interpace’s thyroid products to assess indeterminate nodules providing patients with added diagnostic options. Since ThyGenX was launched in 2014, Interpace has conducted over 25,000 thyroid tests for over 700 physicians and hospitals nationwide.

  • GuruFocus.com

    Interpace Diagnostics Group Inc (IDXG) Files 10-K for the Fiscal Year Ended on December 31, 2018

    Interpace Diagnostics Group Inc is engaged in developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for diagnosis and management. Interpace Diagnostics Group Inc had annual average EBITDA growth of 6.90% over the past five years. Warning! GuruFocus has detected 2 Warning Signs with IDXG.